Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Kann akute Photobiomodulation das Gleichgewicht und die Kognition bei Personen mit Ataxie verbessern: eine Pilot-Machbarkeits-Placebo-randomisierte kontrollierte Studie.

20. September 2026 aktualisiert von: Jonathan Sinclair, University of Central Lancashire

Kann akute Photobiomodulation das Gleichgewicht und die Kognition bei Personen mit Ataxie verbessern: eine Pilot-Machbarkeitsstudie mit Placebo-kontrolliertem randomisierten Versuchsdesign.

Cerebellar ataxias cause progressive impairments in balance, gait coordination, motor timing, and cognitive functions such as attention and executive control (Buckner, 2013; Salmi et al., 2010; Timmann & Daum, 2007). These symptoms substantially reduce independence and quality of life, and current treatments remain limited. There is an urgent need for safe, low-burden interventions that can support everyday functioning and potentially enhance compensatory neural processes.

Transcranial photobiomodulation (tPBM) uses red and near-infrared light (600-1100 nm) to modulate mitochondrial cytochrome-c oxidase, increasing ATP production, reducing oxidative stress, and improving cerebral blood flow (Hamblin, 2016; Salehpour et al., 2019). Several studies show that tPBM can acutely improve cognitive performance and motor control in both healthy adults and clinical groups (Barrett & Gonzalez-Lima, 2013; Chan et al., 2019; Henderson & Morries, 2017). A growing neurobiological literature suggests that light can penetrate posterior cortical areas sufficiently to modulate networks involving cerebellar-cortical loops (Jagdeo et al., 2012).

Importantly for ataxia, preliminary work shows that tPBM may acutely improve balance stability and gait metrics in older adults and patients with neurological conditions (Moro et al., 2022; Shin et al., 2021). In our own laboratory, we have observed immediate improvements in sway range and cognitive control in older adults after a 24-minute tPBM session applied over midline and posterior scalp regions. These medium to large size effects are consistent with enhanced sensorimotor integration and improved control of attention in distracting environments.

Given that individuals with cerebellar ataxia experience both motor incoordination and difficulties in maintaining cognitive stability under distracting conditions, tPBM is a promising non-pharmacological intervention worth preliminary investigation.

Studienübersicht

Status

Noch keine Rekrutierung

Bedingungen

Studientyp

Interventionell

Einschreibung (Geschätzt)

20

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 70 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Age 18-70 years (inclusive)
  • Diagnosis of ataxia
  • Able to walk independently for at least 5 minutes, with or without an assistive device
  • Able to stand safely for balance testing, with or without an assistive device
  • Hemodynamically stable (stable blood pressure and heart rate at rest)
  • On a stable medication regimen for ≥4 weeks prior to enrolment
  • Sufficient vision and hearing (with usual aids if required) to complete balance and cognitive assessments
  • Able to complete study questionnaires and cognitive tasks (with assistance for reading/writing if required)
  • Able and willing to provide written informed consent

Exclusion Criteria:

  • Current or past history of head injury
  • Use of medications acting on the central nervous system
  • Active skin conditions on the forehead or scalp
  • Any other major neurological disorder that could independently affect balance or cognition
  • Ongoing brain stimulation therapy
  • History of migraines
  • Sensitive skin, allergies

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Doppelt

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Placebo-Komparator: Sham Comparator: Sham photobiomodulation

Sham photobiomodulation. The sham device will follow the same protocol but without active light emission.

The sham device will follow the same protocol but without active light emission.

Experimental: Photobiomodulation

Acute photobiomodulation Twenty-four-minute photobiomodulation stimulation (twelve minutes at 670 nm followed by twelve minutes at 810 nm).

Photobiomodulation

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
n-1-back (deviation)
Zeitfenster: Baseline

The n-1-back (deviation) task is a working memory test where participants respond when the current stimulus differs from the one presented n-1 trials earlier.

Baseline
n-1-back (deviation)
Zeitfenster: 1 hour

The n-1-back (deviation) task is a working memory test where participants respond when the current stimulus differs from the one presented n-1 trials earlier.

1 hour

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
n-2-back (deviation)
Zeitfenster: Baseline

The n-2-back (deviation) task is a working memory test where participants respond when the current stimulus differs from the one presented n-2 trials earlier.

Baseline
n-2-back (deviation)
Zeitfenster: 1 hour

The n-2-back (deviation) task is a working memory test where participants respond when the current stimulus differs from the one presented n-2 trials earlier.

1 hour
n-1-back (post-deviation)
Zeitfenster: Baseline

The n-1-back (post-deviation) task assesses working memory performance on the trial immediately following a deviation from the stimulus presented n-1 trials earlier.

Baseline
n-1-back (post-deviation)
Zeitfenster: 1 hour

The n-1-back (post-deviation) task assesses working memory performance on the trial immediately following a deviation from the stimulus presented n-1 trials earlier.

1 hour
n-2-back (post-deviation)
Zeitfenster: Baseline

The n-2-back (post-deviation) task assesses working memory performance on the trial immediately following a deviation from the stimulus presented n-2 trials earlier.

Baseline
n-2-back (post-deviation)
Zeitfenster: 1 hour

The n-2-back (post-deviation) task assesses working memory performance on the trial immediately following a deviation from the stimulus presented n-2 trials earlier.

1 hour
n-1-back (post-target)
Zeitfenster: Baseline

The n-1-back (post-target) task assesses working memory performance on the trial immediately following a target that matched the stimulus presented n-1 trials earlier.

Baseline
n-1-back (post-target)
Zeitfenster: 1 hour

The n-1-back (post-target) task assesses working memory performance on the trial immediately following a target that matched the stimulus presented n-1 trials earlier.

1 hour
n-2-back (post-target)
Zeitfenster: Baseline

The n-2-back (post-target) task assesses working memory performance on the trial immediately following a target that matched the stimulus presented n-2 trials earlier.

Baseline
n-2-back (post-target)
Zeitfenster: 1 hour

The n-2-back (post-target) task assesses working memory performance on the trial immediately following a target that matched the stimulus presented n-2 trials earlier.

1 hour
n-1-back (load)
Zeitfenster: Baseline

The n-1-back (load) condition measures working memory performance under the cognitive demand of tracking stimuli 1 trial back.

Baseline
n-1-back (load)
Zeitfenster: 1 hour

The n-1-back (load) condition measures working memory performance under the cognitive demand of tracking stimuli 1 trial back.

1 hour
n-2-back (post-load)
Zeitfenster: Baseline

The n-2-back (post-load) condition assesses working memory performance on the trial immediately following a high cognitive load in the n-2-back task.

Baseline
n-2-back (post-load)
Zeitfenster: 1 hour

The n-2-back (post-load) condition assesses working memory performance on the trial immediately following a high cognitive load in the n-2-back task.

1 hour
Coop-Wonka chart
Zeitfenster: Baseline

The Coop-Wonka chart is a six item questionnaire with a 1-5 scoring system for each thus the chart has a maximum score of 30 which indicates the lowest possible psychological Wellbeing.

Baseline
Coop-Wonka chart
Zeitfenster: 1 hour

The Coop-Wonka chart is a six item questionnaire with a 1-5 scoring system for each thus the chart has a maximum score of 30 which indicates the lowest possible psychological Wellbeing.

1 hour
Beck Depression Inventory
Zeitfenster: Baseline

Psychological wellbeing - the Beck Depression Inventory is a 21 questionnaire with questions that range in scoring from 0-3, thus the maximum score is 63 which is the highest depression score possible.

Baseline
Beck Depression Inventory
Zeitfenster: 1 hour

Psychological wellbeing - the Beck Depression Inventory is a 21 questionnaire with questions that range in scoring from 0-3, thus the maximum score is 63 which is the highest depression score possible.

1 hour
Pittsburgh Sleep Quality Index
Zeitfenster: Baseline

The Pittsburgh Sleep Quality index, is a questionnaire that consists of 19 self-rated questions, grouped into 7 components. Each component is scored separately, weighted equally on a 0 - 3 scale and the scores of the 7 components are then added to give a global score, which has a range of 0 - 21 with higher scores indicating worse sleep quality.

Baseline
Pittsburgh Sleep Quality Index
Zeitfenster: 1 hour

The Pittsburgh Sleep Quality index, is a questionnaire that consists of 19 self-rated questions, grouped into 7 components. Each component is scored separately, weighted equally on a 0 - 3 scale and the scores of the 7 components are then added to give a global score, which has a range of 0 - 21 with higher scores indicating worse sleep quality.

1 hour
State Trait Anxiety Inventory
Zeitfenster: Baseline

The state trait anxiety inventory is a 40 item questionnaire with each question having a 1-4 score system, thus the maximum score is 80 which indicates the highest level of anxiety.

Baseline
State Trait Anxiety Inventory
Zeitfenster: 1 hour

The state trait anxiety inventory is a 40 item questionnaire with each question having a 1-4 score system, thus the maximum score is 80 which indicates the highest level of anxiety.

1 hour
Insomnia Severity Index
Zeitfenster: Baseline

The Insomnia Severity Index is a brief instrument designed to assess the severity of both nighttime and daytime components of insomnia. The Insomnia Severity Index is a 7-item self-report questionnaire yielding a total score ranging from 0 to 28.

Baseline
Insomnia Severity Index
Zeitfenster: 1 hour

The Insomnia Severity Index is a brief instrument designed to assess the severity of both nighttime and daytime components of insomnia. The Insomnia Severity Index is a 7-item self-report questionnaire yielding a total score ranging from 0 to 28.

1 hour
Epworth Sleepiness Scale
Zeitfenster: Baseline

The Epworth Sleepiness Scale is a self-administered questionnaire with 8 questions. Respondents are asked to rate, on a 4-point scale (0-3) with a maximum score of 24.

Baseline
Epworth Sleepiness Scale
Zeitfenster: 1 hour

The Epworth Sleepiness Scale is a self-administered questionnaire with 8 questions. Respondents are asked to rate, on a 4-point scale (0-3) with a maximum score of 24.

1 hour
Everyday Memory Errors Questionnaire
Zeitfenster: Baseline

The Everyday Memory Errors Questionnaire is a brief self-report instrument designed to assess the frequency of memory lapses in daily life. It consists of multiple items that yield a total score reflecting the extent of everyday memory difficulties.

Baseline
Everyday Memory Errors Questionnaire
Zeitfenster: 1 hour

The Everyday Memory Errors Questionnaire is a brief self-report instrument designed to assess the frequency of memory lapses in daily life. It consists of multiple items that yield a total score reflecting the extent of everyday memory difficulties.

1 hour
Falls Efficacy
Zeitfenster: Baseline

The Falls Efficacy Scale is a brief self-report instrument designed to assess confidence in performing daily activities without falling. It consists of multiple items that yield a total score reflecting fear of falling and perceived fall-related self-efficacy.

Baseline
Falls Efficacy
Zeitfenster: 1 hour

The Falls Efficacy Scale is a brief self-report instrument designed to assess confidence in performing daily activities without falling. It consists of multiple items that yield a total score reflecting fear of falling and perceived fall-related self-efficacy.

1 hour
Anterior-posterior balance
Zeitfenster: Baseline

The maximum anterior-posterior displacement of the centre of pressure during a two-minute balance task.

Baseline
Anterior-posterior balance
Zeitfenster: 1 hour

The maximum anterior-posterior displacement of the centre of pressure during a two-minute balance task.

1 hour
Medio-lateral balance
Zeitfenster: Baseline

The maximum medio-lateral displacement of the centre of pressure during a two-minute balance task.

Baseline
Medio-lateral balance
Zeitfenster: 1 hour

The maximum medio-lateral displacement of the centre of pressure during a two-minute balance task.

1 hour

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

1. Januar 2027

Primärer Abschluss (Geschätzt)

1. Juni 2027

Studienabschluss (Geschätzt)

10. Dezember 2027

Studienanmeldedaten

Zuerst eingereicht

8. Dezember 2025

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

8. Dezember 2025

Zuerst gepostet (Tatsächlich)

22. Dezember 2025

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

22. September 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

20. September 2026

Zuletzt verifiziert

1. September 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren